Scientific data review of prostate cancer patients to study treatment patterns and understand need gaps.

Not Applicable

Conditions: Health Condition 1: N428- Other specified disorders of prostate

Registration Number: CTRI/2024/08/072504

Lead Sponsor: Pfizer Limited

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1. New diagnosis of mCRPC during the case selection window (between 15 April 2019 to 14 January 2022, inclusive). mCRPC is defined as the current and/or historical presence of metastases on any imaging modality with evidence of disease progression (a rising PSA or radiographic progression (as defined by the investigator) despite ongoing castration therapy [LHRH agonist / antagonist or prior surgical

orchiectomy]).

2. Aged at least 18 years upon diagnosis of mCRPC.

Of note, patients may be alive or deceased at the date of data abstraction.

Exclusion Criteria

Previously enrolled in an interventional trial related to CRPC (patients may have been

enrolled in trials of primary treatment and/or hormone-sensitive prostate cancer).

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Describe demographic and clinical characteristics at first diagnosis of mCRPC. <br/ ><br>Document treatment patterns from original prostate cancer diagnosis leading up to, <br/ ><br>upon and following diagnosis of mCRPC. <br/ ><br>Assess clinical outcomes among patients diagnosed with mCRPC, including <br/ ><br>prostate-specific antigen (PSA) response, real-world progression-free survival (PFS), <br/ ><br>real-world objective response rate (ORR), OS, and death by treatment lines. <br/ ><br>Report mCRPC-specific HCRU where applicable <br/ ><br>Document time on treatment for each line of treatment for mCRPC <br/ ><br>Document time to next treatment from initiation of a systemic therapy line to the <br/ ><br>commencement of the subsequent systemic therapy line for mCRPC <br/ ><br>Document time to subsequent chemotherapy from initiation of first-line systemic <br/ ><br>treatment for mCRPCTimepoint: 24 Months

Secondary Outcome Measures